Article Abstract

Prostate cancer and hypofractionation: really a new standard of care?

Authors: Christian Carrie, Ronan Tanguy


The Lancet Oncology published in June 2016 results of the CHHiP trial (1): a randomized phase 3, non-inferiority trial testing a standard radiotherapy treatment for localized prostate cancer (74 Gy in 37 fractions over 7.4 weeks) compare to two more protracted schedules: 60 Gy in 20 fractions/4 weeks or 57 Gy in 19 fractions/3.8 weeks. The majority of enrolled patients had low or intermediate-risk disease and the prognostic factors are well balanced between the three arms. Half of the patients have been treated with no image guidance and only one third have been treated with inverse planning intensity modulated radiation therapy (IMRT) that could be considered today as a standard.